Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 18-24 Jul 2023 Weekly Digest – 18-24 Jul 2023 21 Jul 2023: Opdivo (Nivolumab) / Completely Resected Stage IIB or IIC Melanoma / BMS: Received positive EU CHMP opinion The recommendation was based on results from the […]
Weekly Digest – 10-17 Mar 2023 Weekly Digest – 10-17 Mar 2023 13 Mar 2023: Xtandi (Enzalutamide, Oral)/ mHSPC / Astellas / Pfizer: Phase 3 China ARCHES study meets primary endpoints Announced a clinical hold on its STING agonist ADC […]
Weekly Digest – 10-17 Mar 2023 Weekly Digest – 10-17 Mar 2023 13 Mar 2023: XMT-2056 (IV) / Solid Tumors / Mersana Therapeutics: Announced a clinical hold on its STING agonist ADC in Phase 1 trial Mersana Therapeutics announced a […]
